Neurodevelopmental disorder characterized by by hyperactivity, impulsivity, and/or inattention in multiple settings (school, home, places of worship, etc), not appropriate for a person’s age.
M/C neurobehavioral disorder in children Normal intelligence presentAffects 5% (children & adolescents) and 2.5% (adults) worldwide.
History
History of attention-deficit/hyperactivity disorder. | Faraone, S. V, Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., … Franke, B. (2015). Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers, 1(1), 15020. https://doi.org/10.1038/nrdp.2015.20
Etiology
Genetics of attention-deficit/hyperactivity disorder. | Faraone, S., Asherson, P., Banaschewski, T. et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers 1, 15020 (2015). https://doi.org/10.1038/nrdp.2015.20
Developmental course of attention-deficit/hyperactivity disorder in persistent cases. | Faraone, S. V, Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., … Franke, B. (2015). Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers, 1(1), 15020. https://doi.org/10.1038/nrdp.2015.20
Clinical features
The Calgary Guide | http://calgaryguide.ucalgary.ca/
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) clinical types:
Predominantly inattentive (ADHD-PI or ADHD-I) ≥ 6 hyperactivity-impulsivity symptoms < 6 inattention symptoms Predominantly hyperactive-impulsive (ADHD-PH or ADHD-HI) (M/C sybtype) ≥ 6 inattention symptoms < 6 hyperactivity-impulsivity symptoms Combined type (ADHD-C) ≥ 6 symptoms each of inattention and hyperactivity-impulsivity
Case studies:
…sort of
Diagnosis
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria:
Developmentally inappropriate behaviour compared to normal children of same age Must begin before 12 years age Must last for ≥ 6 months Must be present in ≥ 2 settings Must be reported as such by independent observers Must not be secondary to another disorder
Quality of life and attention-deficit/hyperactivity disorder. | Faraone, S., Asherson, P., Banaschewski, T. et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers 1, 15020 (2015). https://doi.org/10.1038/nrdp.2015.20
Management
Management decision tree. | Faraone, S., Asherson, P., Banaschewski, T. et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers 1, 15020 (2015). https://doi.org/10.1038/nrdp.2015.20
Pharmacological management:
Stimulants: Methylphenidate (DOC), amphetamine and their derivativesNewer mode of administration: Osmotic controlled release oral delivery system (OROS) Alternatives (non-stimulant medications ): Atomoxetine (SNRI), guanfacine , clonidine (α-agonist)
Cognitive behavioural therapy (CBT)
Summary
ADHD. (2015). Nature Reviews Disease Primers, 1(1), 15027. https://doi.org/10.1038/nrdp.2015.27
Related